BSECompany Update23 Oct 2026 · 23 Oct 2026, 12:01 pm
Outcome of the meeting of Preferential Issue Commitee of the Board of Directors of Medicamen Biotech Limited to consider and approve the allotmentb of 5,00,000 Equity Shares pursuant to conversion of 5,00,000 fully convertible warrants at an issue price of Rs. 530/- per Equity Share
Medicamen Biotech Ltd-$ · 531146
✦ AI SummaryFundraise
Medicamen Biotech Ltd has approved the allotment of 5,00,000 equity shares at Rs. 530/- per share to a promoter group entity, Shivalik Rasayan Limited, for an aggregate amount of Rs. 26,50,00,000/-, increasing the company's paid-up equity share capital to Rs. 14,06,28,150/-.
Analysis Scores
Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk5/10
Liquidity Impact8/10
Market Sentiment6/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Medicamen Biotech Ltd-$ - 531146 - Announcement under Regulation 30 (LODR)-Allotment
Attachments (1)
📄pdf
Download →
5546538c-4e47-4975-bc4f-0f15579264e8.pdf
View document text
Date: October 23, 2026
To, To,
Corporate Relationship Department Listing Compliance Department
BSE Limited National Stock Exchange of India Limited,
Phiroze Jeejeebhoy Towers, 25th Floor, Exchange Plaza, 5th Floor, Plot No. C/2, G Block,
Dalal Street, Mumbai – 400 001 Bandra Kurla Complex, Bandra (E),
Mumbai-400051
Scrip Code: 531146 SYMBOL: MEDICAMEQ
Subject: Outcome of the Meeting of Preferential Issue Committee of the Board of Directors of Medicamen
Biotech Limited (“the Company”) in accordance with Regulation 30 of the Securities & Exchange Board
of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dear Sir/Ma’am,
With reference to the captioned subject and in accordance with Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, we hereby inform you that the Preferential Issue Committee of
the Board of Directors of Medicamen Biotech Limited (“the Company”) at their meeting held today i.e.
October 23, 2026, has, inter alia, considered and approved the allotment of 5,00,000 Equity Shares pursuant to
conversion of 5,00,000 Fully Convertible Warrants (“Warrants”) at an issue price of Rs. 530/- per equity share,
for cash, for an aggregate amount of Rs. 26,50,00,000/- on a preferential basis, to the entity belonging to the
‘Promoter and Promoter Group’ category:
S. No. Name of the proposed allottees Category No. of Equity Shares
allottee
1. Shivalik Rasayan Limited Promoter & Promoter Group 5,00,000
Total 5,00,000
Consequent to the said allotment, the Paid-up Equity Share Capital of the Company stands increased to
Rs. 14,06,28,150/- comprising of 1,40,62,815 Equity Shares of face value of Rs. 10/- each.
The meeting of Preferential Issue Committee of the Board of Directors commenced at 11.00 AM and concluded
at 11.45 AM
This is for your information and records.
Thanking You,
Yours Faithfully,
For Medicamen Biotech Limited
Parul Choudhary
Company Secretary & Compliance Officer